FeesSafety
Pluang+

Eli Lilly's weight loss drugs drive 39% revenue surge, fueling strong growth outlook.

Market News
22 Nov 2026, 11:10 WIB
The Motley Fool
View Source
Bullish
Eli Lilly's weight loss drugs drive 39% revenue surge, fueling strong growth outlook.

Eli Lilly has seen its revenue soar thanks to its dominance in the weight loss drug market, with products like Mounjaro and Zepbound contributing to a 39% revenue increase to over $24 billion recently. The company leads in GLP-1 drugs, which regulate appetite and blood sugar, and has expanded its portfolio with a new oral drug, Foundayo. With a promising pipeline including retatrutide in phase 3 trials, Lilly is positioned for continued growth, though another 400% gain in stock price over five years is unlikely. Still, double- or triple-digit gains remain possible, making it an attractive buy for investors.

Eli Lilly's stock trades at USD 1,347.11 on Pluang as of Nov 22, 2026, 16:31 WIB, showing a slight 0.30% decrease in the last day. The company holds a substantial market cap of $1.20 trillion, reflecting its strong position in the health sector. Despite recent selling pressure with 97% of Pluang orders being sell orders, the stock remains a notable player in its industry.

More News (LLY)

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and showing improved health markers. This success could lead to lab...

Company Fundamentals
Bullish
16 hours ago
Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Novo Nordisk lost its lead in the GLP-1 weight-loss shot market to Eli Lilly due to supply issues but has rebounded strongly with its new GLP-1 pill, which captured 80% of new oral treatment patients in Q3 2026. The company is shifting to a volume-dr...

Market News
Bullish
16 hours ago
Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and notable improvements in health markers. This success could lead...

Company Fundamentals
Bullish
21 hours ago
AbbVie offers better value while Eli Lilly leads in growth for 2027 pharma portfolios.

AbbVie offers better value while Eli Lilly leads in growth for 2027 pharma portfolios.

AbbVie and Eli Lilly are key pharmaceutical players with distinct strengths for 2027. AbbVie focuses on immunology and aesthetics with solid cash flow and a lower valuation, making it a value pick. Eli Lilly dominates metabolic health with rapid reve...

Market News
Bullish
1 day ago
$1,000 invested in Eli Lilly 10 years ago is now worth over $20,500, driven by blockbuster diabetes and obesity drugs.

$1,000 invested in Eli Lilly 10 years ago is now worth over $20,500, driven by blockbuster diabetes and obesity drugs.

Eli Lilly's stock has surged dramatically over the past decade, with a $1,000 investment growing to more than $20,500, thanks mainly to its diabetes and obesity drugs like Mounjaro (tirzepatide) and Zepbound. The company, now valued at over $1.2 tril...

Company Fundamentals
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App